Elanco Animal Health Incorporated (ELAN)

NYSE · Drug Manufacturers - Specialty & Generic

23.59
-0.02 (-0.08%)
Updated Aug 18, 6:46 PM ET
AI Rating
Hold
Overall Score
50
Trend
52
Momentum
36
Risk
68

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Feb 20, 2026 120 sessions Aug 14, 2026

AI Analysis

Elanco Animal Health Incorporated is trading at $23.59, down 0.08% on the session. The 50 day average sits at $24.49 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 46.2, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $23.07 with resistance near $25.07, so that band frames the current range. Average daily movement is roughly $1.16, or about 4.9% of the share price, which is what any stop placement has to allow for. The overall health score of 50 out of 100 combines a trend score of 52, momentum of 36 and a risk score of 68.

Technical indicators

RSI (14)
46.2
neutral
MACD
-0.528
bearish crossover
SMA 20
24.70
SMA 50
24.49
SMA 200
--
unknown
ATR (14)
1.16
avg daily range
Support
23.07
Resistance
25.07
Volume vs 20d
0.79x
below average
Volatility
54.3%
annualised
1 month
-7.36%
3 months
+10.45%

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.